Yoo A S, Cheng I, Chung S, Grenfell T Z, Lee H, Pack-Chung E, Handler M, Shen J, Xia W, Tesco G, Saunders A J, Ding K, Frosch M P, Tanzi R E, Kim T W
Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown 02129, USA.
Neuron. 2000 Sep;27(3):561-72. doi: 10.1016/s0896-6273(00)00066-0.
We studied a novel function of the presenilins (PS1 and PS2) in governing capacitative calcium entry (CCE), a refilling mechanism for depleted intracellular calcium stores. Abrogation of functional PS1, by either knocking out PS1 or expressing inactive PS1, markedly potentiated CCE, suggesting a role for PS1 in the modulation of CCE. In contrast, familial Alzheimer's disease (FAD)-linked mutant PS1 or PS2 significantly attenuated CCE and store depletion-activated currents. While inhibition of CCE selectively increased the amyloidogenic amyloid beta peptide (Abeta42), increased accumulation of the peptide had no effect on CCE. Thus, reduced CCE is most likely an early cellular event leading to increased Abeta42 generation associated with FAD mutant presenilins. Our data indicate that the CCE pathway is a novel therapeutic target for Alzheimer's disease.
我们研究了早老素(PS1和PS2)在调控钙池调控性钙内流(CCE)中的新功能,CCE是一种用于补充耗尽的细胞内钙库的再填充机制。通过敲除PS1或表达无活性的PS1来消除功能性PS1,可显著增强CCE,这表明PS1在调节CCE中发挥作用。相反,与家族性阿尔茨海默病(FAD)相关的突变型PS1或PS2显著减弱了CCE和储存耗竭激活电流。虽然抑制CCE选择性地增加了淀粉样蛋白生成的淀粉样β肽(Aβ42),但该肽积累的增加对CCE没有影响。因此,CCE降低很可能是导致与FAD突变早老素相关的Aβ42生成增加的早期细胞事件。我们的数据表明,CCE途径是阿尔茨海默病的一个新的治疗靶点。